VideoHIVInternational Workshop on HIV Pediatrics 2020Development and Validation of the HIV Adolescent Readiness for Transition Scale (HARTS) - Brian ZanoniView Video
VideoHIVInternational Workshop on HIV Pediatrics 2020Factors Associated with Late Presentation of HIV-Infected Infants for Early Infant HIV Diagnosis (Eid) Services in Kenya - Agnes LangatView Video
VideoHIVInternational Workshop on HIV Pediatrics 2020Finding the Remaining Unidentified Children Living with HIV: Opportunities Through Index Testing - Megan GleasonView Video
VideoHIVInternational Workshop on HIV Pediatrics 2020“Right Under Our Nose”: A Simple Screening Tool to Identify HIV-Positive Children Outside of the PMTCT Program at Outpatient Departments in Malawi - Anna TallmadgeView Video
VideoHIVInternational Workshop on HIV Pediatrics 2020Point of Care Samba-Ii Vs Centralized Laboratory Viral Load Assays Among HIV-1 Infected Children, Adolescents and Young Adults in Rural Zimbabwe: A Randomized Controlled Trial - Vinie KouamouView Video
VideoHIVInternational Workshop on HIV Pediatrics 2020A Validated Outpatient Department HIV Screening Tool for Children 18 Months To 14 Years as Efficient as Index Testing in Uganda - Rhoderick MachekanoView Video
VideoHIVInternational Workshop on HIV Pediatrics 2020Acceptability of a New 4-In-1 Abacavir/Lamivudine/Lopinavir/Ritonavir Paediatric Fixed- Dose Combination: The Caregiver-Child Dyads’ Perspective - Ogara CollinView Video
VideoHIVInternational Workshop on HIV Pediatrics 2020The “Dtgs” of DTG for Children and Adolescents Living with HIV (CALHIV): Descriptions, Trends, and Gaps of Rolling Out Dolutegravir in CALHIV In Mbeya, Tanzania - Jason Bacha, TanzaniaView Video
VideoHIVInternational Workshop on HIV Pediatrics 2020Safety, Pharmacokinetics And Acceptability Of The Abc/3tc/Lpv/R Granules (4-In-1) In Children Living With HIV (3-20kg) In Uganda: LOLIPOP Study - Juliet MwangaView Video
VideoHIVInternational Workshop on HIV Pediatrics 2020Safety, Pharmacokinetics, and Efficacy of Low-Dose E/C/F/TAF in Virologically Suppressed Children ≥2 Years Old Living with HIV - Eva NatukundaView Video
VideoHIVInternational Workshop on HIV Pediatrics 2020Pediatric Dolutegravir (DTG) Dosing Recommendations Derived from Combined P1093 and ODYSSEY Population Pharmacokinetic Analysis - Rajendra SinghView Video
VideoHIVInternational Workshop on HIV Pediatrics 2020Twenty-Four Week Safety, Tolerability and Efficacy of Dolutegravir Dispersible Tablets in Children 4 Weeks to <6 Years Old with HIV: Results from IMPAACT P1093 - Theodore RuelView Video
